News

We were thrilled to see the recent BBC News coverage highlighting the encouraging progress of Alyssa, as well as 8 other children and 2 adults enrolled in the clinical trial led by Professor Waseem Qasim and delivered through the exceptional teams at UCL and Great Ormond Street Hospital. Stories like this serve as a powerful reminder of why this field matters. Every vector we manufacture has the potential to impact a real person, a real family, and a real future. Seeing positive progress in this patient’s journey is incredibly motivating for our team.

We are proud that the GMP-grade viral vector enabling this trial was manufactured here at the King’s College London Gene Therapy Vector Facility (GTVF).

https://www.bbc.co.uk/news/articles/cj38ymeyg4mo

We specialise in the manufacture of GMP viral vectors to support early-phase clinical trials. Our facility is designed specifically to bridge the gap between the bench and clinical application, combining rigorous regulatory compliance, process development, and scalable GMP manufacturing. This trial exemplifies how academic-embedded manufacturing capabilities can accelerate translational progress and bring promising therapies closer to the patients who need them.

At the heart of all our work is patient impact. We remain committed to supporting organisations developing life-changing advanced therapies. Many congratulations to Professor Waseem Qasim and the teams at UCL and Great Ormond Street Hospital on their trial.

If you are an academic investigator, charity, spin-out, or industry therapy developer preparing for early-stage or first-in-human studies and require GMP viral-vector manufacturing, get in touch via the contact us link, we would be delighted to help.